Cited by 222Immunotherapy and Immune ResponsesVirus-based gene therapy researchBacterial Cancer Therapy

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Viral Vector-Based Therapeutic Cancer Vaccines

Open access

Larocca, Cecilia, Schlom, Jeffrey·2011·The Cancer Journal

DOI 10.1097/ppo.0b013e3182325e63PMC PMC3207353

Open this paper in CoChat — free account

Abstract

Most viruses are naturally immunogenic and can be engineered to express tumor antigen transgenes. Moreover, many types of recombinant viruses have been shown to infect professional antigen-presenting cells, specifically dendritic cells, and express their transgenes. This enhanced presentation of tumor antigens to the immune system has led to an increase in the frequency and avidity of cytotoxic T lymphocytes that target tumor cells expressing the tumor antigen(s) encoded in the vaccine vector. Logistically, recombinant viruses can be produced, administered, and quality controlled more easily compared with other immunotherapy strategies. The intrinsic properties of each virus have distinct advantages and disadvantages, which can determine their applicability in a particular therapeutic setting. The disadvantage of some vectors is the development of host-induced neutralizing antibodies to the vector itself, thus limiting its continued use. The "off-the-shelf" nature of viral vaccine platforms renders them exceptionally suitable for multicenter randomized trials. This review described and discussed the strategies used and results using viral-based vaccines, with emphasis on phases II and III clinical trials. Future directions will involve the evaluation of viral-based vaccines in the adjuvant and neoadjuvant settings, in patients with low burden metastatic disease, and in combination with other forms of therapy including immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ppo.0b013e3182325e63

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,456
Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andrès, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,103
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 994
Self-citation
Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution
House, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine
Tsang, K.-Y., Zaremba, S., Nieroda, C. A., Zhu, M., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citation
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marté, J. L., Beetham, P. K., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370
Self-citation
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E. S., Pedicano, J. E., Gehan, E. A., Peck, R. A., Arlen, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 356
Self-citation

Flagged first, then by citations

Show all 85 references

Sorted by citations

Items 101–200 of 222

Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy
Kumari, K., Singh, A., Chaudhary, A., Singh, R. K., Shanker, A., Kumar, V., & Haque, R. (2024) · Vaccines · doi:10.3390/vaccines12050498 · Cited by 20
Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
Goossens, M., Pauwels, K., Willemarck, N., & Breyer, D. (2014) · Current Gene Therapy · doi:10.2174/156652321306140103221941 · Cited by 19
Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies
Kelly, M., McNeel, D. G., Fisch, P., & Malkovský, M. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.11.001 · Cited by 17
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
Flickinger, J. C., Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A. M., Waldman, S. A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00483-z · Cited by 16
Immunotherapy for Ovarian Cancer: Disappointing or Promising?
Deng, M., Tang, F., Chang, X., Liu, P., Ji, X., Hao, M., Wang, Y., Yang, R., Ma, Q., Zhang, Y., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00986 · Cited by 18
The progress of tumor vaccines clinical trials in non-small cell lung cancer
Wang, X., Niu, Y., & Bian, F. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03678-z · Cited by 16
Therapeutic Cancer Vaccines
Ye, Z., Li, Z., Jin, H., & Qian, Q. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_3 · Cited by 16
Current and emerging EGFR therapies for glioblastoma
Artene, Ş.-A., Tuţă, C., Dragoi, A., Alexandru, O., Purcaru, Ş. O., Tache, D. E., Dănciulescu, M. M., Boldeanu, M. V., Siloşi, C. A., & Dricu, A. (2018) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2017.1411816 · Cited by 16
Immune Targeting of Tumor Epithelial–Mesenchymal Transition via Brachyury-Based Vaccines
Palena, C., & Hamilton, D. H. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.001 · Cited by 15
Immunotherapy for HPV negative head and neck squamous cell carcinoma
Jiang, B., Elkashif, A., Coulter, J. A., Dunne, N., & McCarthy, H. O. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189138 · Cited by 17
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy
Drakes, M. L., & Stiff, P. J. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s37790 · Cited by 15
Immunotherapy: Constructive Approach for Breast Cancer Treatment
Anayyat, U., Ahad, F., Muluh, T. A., Zaidi, S. H. E., Usmani, F., Yang, H. W., Li, M., Hassan, H. A., & Wang, X. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s424624 · Cited by 14
Is there still hope for the prophylactic hepatitis C vaccine? A review of different approaches
Rzymski, P., Jibril, A. T., Rahmah, L., Abarikwu, S. O., Hashem, F., Lawati, A. A., Morrison, F. M. M., Marquez, L. P., Mohamed, K., Khan, A., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29900 · Cited by 13
Bacteriophages: cancer diagnosis, treatment, and future prospects
Abbaszadeh, F., Leylabadlo, H. E., Alinezhad, F., Feizi, H., Mobed, A., Baghbanijavid, S., & Baghi, H. B. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00503-x · Cited by 14
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
Chiang, C. L.-L., Rovelli, R., Sarivalasis, A., & Kandalaft, L. E. (2021) · Cancers · doi:10.3390/cancers13184553 · Cited by 13
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Bendjama, K., & Quéméneur, É. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1334746 · Cited by 14
Current status and future of cancer vaccines: A bibliographic study
Yu, R., Zhao, F., Xu, Z., Zhang, G., Du, B., & Shu, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24404 · Cited by 12
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Kaliński, P., Nguyen, T. K., & Urban, J. A. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s40264 · Cited by 12
Breast cancer vaccination: Latest advances with an analytical focus on clinical trials
Vajari, M. K., Sanaei, M., Salari, S., Rezvani, A., Ravari, M. S., & Bashash, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110696 · Cited by 10
A mathematical model for the role of macrophages in the persistence and elimination of oncolytic viruses
Almuallem, N. A., & Eftimie, R. (2020) · Mathematics in Applied Sciences and Engineering · doi:10.5206/mase/8543 · Cited by 11
Overview of virus and cancer relationships. Position paper
Bouza, E., Jiménez, M. M., Alemany, L., Arribas, J., Bañares, R., Barragán, M. B., Bouza, J. M. E., Felip, E., Fernández-Capetillo, Ó., Gracia, D., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/058.2021 · Cited by 11
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Delgado-Almenta, V., Blaya-Cánovas, J. L., Calahorra, J., López-Tejada, A., Griñán‐Lisón, C., & Granados-Principal, S. M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020216 · Cited by 10
Development of Cancer Immunotherapies
DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 10
The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies
Ling, Q., Zheng, B., Chen, X., Ye, S., & Cheng, Q. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2143698 · Cited by 10
A Vector Based on the Chicken Hypersensitive Site 4 Insulator Element Replicates Episomally in Mammalian Cells
Zhang, X., Wang, X., Jia, Y., Guo, X. H., Wang, Y., & Wang, T. (2017) · Current Gene Therapy · doi:10.2174/1566523217666170202122755 · Cited by 10
Next-generation immunotherapy: igniting new hope for lung cancer
Li, M. S. C., Chan, A. L. S., Mok, K. K. S., Chan, L. L., & Mok, T. S. K. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241302021 · Cited by 9
Dendritic Cell-Specific Delivery of Flt3L by Coronavirus Vectors Secures Induction of Therapeutic Antitumor Immunity
Perez‐Shibayama, C., Gil‐Cruz, C., Nussbacher, M., Allgäuer, E., Cervantes‐Barragán, L., Züst, R., & Ludewig, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081442 · Cited by 9
Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip
Suryavanshi, P., & Bodas, D. (2024) · Nanotheranostics · doi:10.7150/ntno.87818 · Cited by 9
Cancer Vaccines: Can They Improve Survival?
Dillman, R. O. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1805 · Cited by 8
Vaxvec: The first web-based recombinant vaccine vector database and its data analysis
Deng, S., Martin, C., Patil, R., Zhu, F., Zhao, B., Xiang, Z., & He, Y. O. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.113 · Cited by 8
New Developments in Therapeutic HPV Vaccines
Lin, J.-Y., Xu, J., Albers, A. E., & Kaufmann, A. M. (2012) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-012-0015-6 · Cited by 8
Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma
Alrumaihi, F., Alromaihi, R. A., Kumar, V., & Anwar, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121056 · Cited by 8
Manufacturing and Financial Evaluation of Peptide-Based Neoantigen Cancer Vaccines for Triple-Negative Breast Cancer in the United Kingdom: Opportunities and Challenges
Novakova, A., Morris, S. A., Vaiarelli, L., & Frank, S. (2025) · Vaccines · doi:10.3390/vaccines13020144 · Cited by 8
Viral Vectors for Vaccine Development
Qiana, L., Gu, L., Krendelchtchikov, A., & Zan, C. (2013) · InTech eBooks · doi:10.5772/54700 · Cited by 7
Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation
Rosinski, S. L., Stone, B. C., Graves, S. S., FULLER, D. H., Rosa, S. C. D., Spies, G. A., Mize, G. J., Fuller, J. T., & Storb, R. F. (2015) · Transplantation · doi:10.1097/tp.0000000000000744 · Cited by 7
Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Hoo, W. P. Y., Siak, P. Y., & In, L. L. A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190904163524 · Cited by 7
Immunological aspects of heat shock protein functions and their significance in the development of cancer vaccines
Boliukh, I., Rombel‐Bryzek, A., & Radecka, B. S. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0024 · Cited by 7
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 7
Unlocking cancer vaccine potential: What are the key factors?
Grant, M. D., Lee, L. N., Chinnakannan, S. K., Tong, O., Kwok, J., Cianci, N., Tillman, L., Saha, A., Almeida, V. P., & Leung, C. S. K. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2331486 · Cited by 6
Vaccine-based therapeutic interventions in lung cancer management: A recent perspective
Gupta, D., Gupta, D. S., Abjani, N. K., Dave, Y., Apte, K., Kaur, G., Kaur, D., Saini, A. K., Sharma, U., Haque, S., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02489-0 · Cited by 6
An Up-to-date Review on Protein-based Nanocarriers in the Management of Cancer
Almalki, W. H. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230509101020 · Cited by 6
Antiproliferative effect of double suicide gene delivery mediated by polyamidoamine dendrimers in human Tenon's capsule fibroblasts
Yang, J., Liu, S., Sun, H. M., & Wang, Y. M. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5235 · Cited by 6
Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
Pliquet, É., Ruffié, C., Escande, M. C., Thalmensi, J., Najburg, V., Combredet, C., Bestetti, T., Julithe, M., Liard, C., Huet, T., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2272-3 · Cited by 6
Next Generation Therapeutic Strateg‐Es: Evolving cancer immunotherapy through agents that Engage, Expand and Enable the anti‐tumor immune response
Wolfson, B., & Hodge, J. W. (2021) · ImmunoMedicine · doi:10.1002/imed.1020 · Cited by 6
Harnessing the immune system and developing targeted vaccines: overall strategies of leveraging the body’s natural defense mechanisms to enhance cancer treatment
Banday, A. H. (2025) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-25-00011 · Cited by 5
Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer
Moseman, J. E., Shim, D., Jeon, D., Rastogi, I., Schneider, K. M., & McNeel, D. G. (2025) · Vaccines · doi:10.3390/vaccines13090976 · Cited by 5
Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities
Chen, M., Zhou, Y. X., Fù, Y., Wang, Q., Wu, C., Pan, X., & Quan, G. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2388832 · Cited by 5
Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances
Sanaei, M., Pourbagheri‐Sigaroodi, A., Rezvani, A., Zaboli, E., Salari, S., Masjedi, M. R., & Bashash, D. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122652 · Cited by 6
Multiplex Real-Time PCR Assay for the Detection and Differentiation of Poxviruses and Poxvirus Vectors
Stellberger, T., Stockmar, I., Haase, M., Meyer, H. E., Zoeller, G., Pavlovic, M., Büttner, M., Konrad, R., Lang, H., Tischer, B. K., et al. (2015) · Applied Biosafety · doi:10.1177/153567601502000405 · Cited by 5
Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer inï¿½vitro
Hao, S., Du, X., Song, Y., Ren, M., Yang, Q., Wang, A., Wang, Q., Zhao, H., Du, Z., & Zhang, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8148 · Cited by 5
Advances and Challenges in Immunotherapy for Metastatic Uveal Melanoma: Clinical Strategies and Emerging Targets
Grigoruţă, M., Kong, X., & Qin, Y. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145137 · Cited by 4
Viruses Are Part of the Holobiont’s Fitness and Evolution
ROSENBERG, E. B. (2021) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-030-65317-0_7 · Cited by 5
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms
Pazoki, A., Dadfar, S., Alirezaee, A., Oksenych, V., & Haghmorad, D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1617352 · Cited by 4
Protein-based nanomedicines as anticancer drug delivery platforms
Rahman, M., Alam, K., Hafeez, A., Ilyas, R., & Beg, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821095-6.00005-7 · Cited by 4
Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects
Kothari, N. R., Postwala, H. I., Pandya, A. J., Shah, A. C., Shah, Y. B., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02003-y · Cited by 4
Non-cellular immunotherapies in pediatric central nervous system tumors
Rumler, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242911 · Cited by 4
Image-Guided Intratumoral Delivery of Immunotherapeutics in Gastrointestinal Malignancies
Qiao, Y., Sheth, R. A., & Tam, A. L. (2021) · Digestive Disease Interventions · doi:10.1055/s-0040-1718389 · Cited by 4
DC-targeting lentivectors for cancer immunotherapy
Gea‐Mallorquí, E., & Rowland‐Jones, S. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad023 · Cited by 4
Gene Therapy and Virus-Based Cancer Vaccines
Salem, M. L., Gadalla, K. K. E., Fielding, B. C., & Thorne, S. H. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_7 · Cited by 3
Comparison of Three Different Methods of Transfection for the Production of Recombinant Adenovirus Expressing Human Carcinoembryonic Antigen Gene.
Yari, A., Bamdad, T., & Hosseini, S. Y. (2023) · PubMed Central · doi:10.22092/ari.2021.354824.1651 · Cited by 3
Pilot clinical trial of DNA vaccination against neuroblastoma: study design and preliminary results
Proleskovskaya, I. V., Meleshko, A., Vashkevich, K., & Konoplya, N. E. (2024) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2023-10-4-11-34-43 · Cited by 3
Poly(vinyl alcohol) (PVA) for gene delivery: A systematic review
Santos, J. D. A., Valente, A. J. M., & Muniz, E. C. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106149 · Cited by 4
Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer
Sun, L., Liu, C., & Peng, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010052 · Cited by 3
Natural carrier systems in cancer vaccines and immunotherapy
Owliaee, I., Shoushtari, M. M., Karimi, Z., & Shojaeian, A. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2535787 · Cited by 3
Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
Zhang, S., Li, S., Wei, Y., Xiong, Y., Liu, Q., Hu, Z., Zeng, Z., Tang, F., & Ouyang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.879278 · Cited by 3
Cell membrane vaccine delivery system: A review of the recent advances against breast cancer
Hilles, A. R., Mahmood, S., Widodo, R. T., Azemi, A. K., Nordin, A. H., Norpi, A. S. M., Jalil, M. F. A., Sofian, Z. M., Mohamed, M., Hambali, K. A., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125849 · Cited by 2
Shaping Antitumor Immunity with Peptide Vaccines: Implications of Immune Modulation at the Vaccine Site
Sarkar, A., Rabinovich, E. P., & Slingluff, C. L. (2025) · Vaccines · doi:10.3390/vaccines13111150 · Cited by 2
A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes
Zhang, W., Chen, M., & Huang, X. (2026) · Research · doi:10.34133/research.1193 · Cited by 3
A polymerase mechanism-based strategy constructing attenuated clones of enterovirus for vaccine vector development
Ji, C., Zhang, Y., Feng, Y., Zhang, X., Wang, K., Ma, J., Pan, Z., & Yao, H. (2023) · Virology · doi:10.1016/j.virol.2023.01.007 · Cited by 2
Recombinant TRICOM-based Therapeutic Cancer Vaccines
Schlom, J., Hodge, J. W., Palena, C., Greiner, J. W., Tsang, K.-Y., Farsaci, B., Madan, R. A., & Gulley, J. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00020-8 · Cited by 2
Self-citation
Cancer Vaccines in Pediatrics
Nakajima, M., & Modak, S. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_10 · Cited by 2
Delivery strategies for cancer vaccines and immunoadjuvants
Graham-Gurysh, E. G., Carpenter, B. W., Beck, W. A., Varma, D. M., Vincent, B. G., Bachelder, E. M., & Ainslie, K. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00014-2 · Cited by 2
Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity
Ellis, A. A., Geary, S. M., & Salem, A. K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122932 · Cited by 2
Tumours: Immunotherapy
Johnson, C. B., Salem, M. L., Mehrotra, S., Cole, D. J., & Rubinstein, M. P. (2013) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0001432.pub3 · Cited by 2
The Effectiveness of Antitumor Vaccine Enriched with a Heat Shock Protein 70
Диденко, Г. В., Круць, О. О., Skivka, L. M., & Prylutskyy, Y. І. (2018) · Heat shock proteins · doi:10.1007/978-3-319-89551-2_17 · Cited by 1
Cancer Vaccines: Another Aspect to Immunotherapy
Al-Janabi, I. I. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v7i1.1057 · Cited by 2
Prostate Cancer Vaccines: Progress, Challenges, and Future Directions
Runtunuwu, S. V. B. E., Tallei, T. E., & Turalaki, G. L. A. (2025) · Heca Journal of Applied Sciences · doi:10.60084/hjas.v3i1.263 · Cited by 1
Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms
Weber, L. G., & Wolff, M. W. (2026) · Expert Review of Vaccines · doi:10.1080/14760584.2026.2689611 · Cited by 1
Therapeutic Cancer Vaccines: Mechanisms, Clinical Progress, and Future Directions
Wilson, K., Banda, J. F., Bukkapatnam, S., Raza, F., & Massarelli, E. (2026) · Vaccines · doi:10.3390/vaccines14070599 · Cited by 1
Approaches to cancer vaccination
Nwonu, E. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91146-7.00003-2 · Cited by 1
Virotherapy in Head and Neck Cancer
Wang, Z. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2023.100151 · Cited by 1
The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors
Schlom, J., Palena, C., Gulley, J. L., Greiner, J. W., Tsang, K.-Y., Madan, R. A., & Hodge, J. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394295-1.00022-6 · Cited by 1
Self-citation
A Review on Anticancer Peptide‐Based Vaccines: Advantages, Limitations and Current Challenges
Ibrahim, N. A. M. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3312376 · Cited by 1
Cancer Vaccines
Murias, C., Arkenau, H., Dutoit, V., & Patrikidou, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.89074 · Cited by 1
Therapeutic Proteins: Blood Products, Vaccines and Enzymes
Walsh, G. (2015) · doi:10.1002/9781119117599.ch6 · Cited by 1
Functional Characterization of the Evolutionarily Conserved Adenoviral Proteins L4-22K and L4-33K
Östberg, S. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Characterization of Vaccinia virus MVA candidate vaccines mutated in viral genes modulating inflammasome activation
Müller, K. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.22017 · Cited by 1
Molecular Farming and Anticancer Vaccine
Ratre, Y. K., Mehta, A., Shinde, S., Sinha, V., Soni, V. K., Sonkar, S. C., Shukla, D., & Vishvakarma, N. K. (2023) · doi:10.1002/9781119874096.ch17 · Cited by 1
Viruses are Part of the Holobiont’s Fitness and Evolution
ROSENBERG, E. B., & Zilber‐Rosenberg, I. (2013) · Springer eBooks · doi:10.1007/978-3-319-04241-1_7
Current Tactics Employed in Cancer Vaccines and Their Progress
Sjuts, A. C., & Brown, A. (2014) · Biochemistry and Molecular Biology Education
Surgical Stress Attenuates Pre-existing Anti-tumour Immunity Resulting in Postoperative Metastases and local Recurrence in a Murine Model
Ananth, A. A. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-6648
UNIVERSITÁ DEGLI STUDI DI MILANO FACOLTÁ DI MEDICINA E CHIRURGIA
Ricerca, D. D. (2010)
MINIREVIEW Replicating poxviruses for human cancer therapy
Kim, M. (2015)
Assembly and characterization of a cell-particle hybrid system as a potential cancer vaccine
Ahmed, K. K., Salem, A. K., & Donovan, M. (2013) · doi:10.17077/etd.icy3h1wl
The Future in Ovarian Cancer: Advances in Immunotherapies
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_11
The impact of Immunotherapy on Ovarian Cancer
Alsunbul, F. O. (2016)
Delivery of immunomodulatory miRNAs using genetically modified influenza viruses
Xia, Y. (2017) · Figshare
Cancer Immunotherapy and Biological Cancer Treatments
Arnouk, H. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77856
Современный подход в иммунотерапии рака
Gavrilov, A. Y., Сенніков, І. А., Lesnoy, V. V., Lesnay, A. S., & Полякова, В. В. (2020) · Experimental and Clinical Medicine · doi:10.35339/ekm.2019.01.02
Gene Therapy and Genetic Vaccines
Hemmati, S., Keshavarz‐Fathi, M., Razi, S., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_7

Authors: Larocca, C., & Schlom, J.
Affiliations: National Institutes of Health (US)
National Cancer Institute (US)
Corresponding author: Larocca, Cecilia
ORCID: Larocca, Cecilia
Schlom, Jeffrey
Venue: The Cancer Journal
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-09
Volume: 17
Issue: 5
Pages: 359-371
ISSN: 1528-9117 (ISSN-L)
DOI: 10.1097/ppo.0b013e3182325e63
PMC: PMC3207353
OpenAlex: W2076096828
Cited by: 222
References: 85
Citations by year: 2026: 7 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 9 · 2015: 17 · 2014: 17 · 2013: 15 · 2012: 5
FWCI: 1.06
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: The Cancer Journal (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (ZIABC010425)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: viral vector vaccines, therapeutic cancer vaccines, dendritic cells, antigen presentation, cytotoxic T lymphocytes, neutralizing antibodies, recombinant virus, neoadjuvant and adjuvant therapy, metastatic cancer, combination immunotherapy, clinical trials
MeSH terms: Antigens, Neoplasm, Clinical Trials as Topic, Genetic Vectors, Humans, Male, Prostatic Neoplasms, Viral Vaccines, Viruses, Vaccines, DNA, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Viral Vector-Based Therapeutic Cancer Vaccines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks